Observational cohort study reveals low COVID-19 infection rates in transplant recipients receiving tixagevimab/cilgavimab, suggesting its role in immunocompromised prophylaxis.
The COVID‐19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®‐treated recipients experienced moderate to severe COVID‐19 infection, with two deaths from COVID‐19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: